This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

IncellDx, Inc. Announces An Agreement With BioReference Laboratories, Inc. To Conduct A 10,000 Sample Study Using A Slideless Pap Smear

MENLO PARK, Calif., Sept. 12, 2012 /PRNewswire/ -- IncellDx, Inc. announced today that it has initiated a large-scale study called SLIQUE ( study to compare s lideless and li quid-based Pap sm ears). The study is being conducted in partnership with BioReference Laboratories, Inc. (NASDAQ: BRLI) and is expected to take anywhere from three to six months.  Over 10,000 samples will be used to compare the performance of OncoTect 3Dx technology with liquid-based cytology (ThinPrep and SurePath ) methods. IncellDx recently presented on OncoTect 3Dx at the Eurogin Conference ( http://www.eurogin.com/2012) and this study represents the next step in commercializing the technology.

Current Pap smear technology is slide-based and requires manual review of each slide by specially trained technicians, increasing cost and reducing throughput. OncoTect 3Dx uses a proprietary flow cytometry-based technology to improve and automate the process. "Liquid-based cytology represents an approximately $5 billion market opportunity for IncellDx," said Bruce Patterson, MD, CEO and Founder of IncellDx. "Our OncoTect 3Dx technology has the potential to increase the sensitivity and specificity of the liquid-based Pap smear while it simultaneously reduces the cost and turnaround time."

"This is a very interesting technology that opens up new horizons as we continue to innovate in the women's health space," said Marc Grodman, MD, CEO of BioReference Laboratories and Chairman of the Board of IncellDx. "We expect that OncoTect 3Dx has the potential to be disruptive in the marketplace both here in the United States and anywhere in the world where cytology resources are scarce."

IncellDx and BioReference expect the study to provide sufficient data to plan a FDA trial for the OncoTect 3Dx technology.

More information about OncoTect ® and OncoTect 3Dx :

About IncellDx, Inc.   IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant rejection. For more information, please visit www.incelldx.com.

ThinPrep is a trademark owned by Hologic and SurePath is a trademark owned by BD.

SOURCE IncellDx, Inc.

Stock quotes in this article: BRLI 
Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs